Nurix Therapeutics Inc (NRIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 11/30
| 02-2020 | 11-2019 | 08-2019 | 05-2019 | 11-2018 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -12,391 | -21,699 | -8,180 | -5,753 | -9,428 |
| Depreciation Amortization | 499 | 2,245 | 1,696 | 1,143 | 2,634 |
| Accounts payable and accrued liabilities | 298 | N/A | 259 | -211 | N/A |
| Other Working Capital | 52,688 | 19,545 | 19,490 | -18,620 | -25,306 |
| Other Operating Activity | -122 | 510 | 84 | 418 | 425 |
| Operating Cash Flow | $40,972 | $601 | $13,349 | $-23,023 | $-31,675 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -364 | -1,651 | -698 | -205 | -1,589 |
| Purchase Of Investment | -19,060 | N/A | -5,939 | -5,939 | N/A |
| Sale Of Investment | N/A | N/A | 19,500 | 15,500 | N/A |
| Other Investing Activity | 0 | 10,149 | 0 | 0 | 41,583 |
| Investing Cash Flow | $-19,424 | $8,498 | $12,863 | $9,356 | $39,994 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 47 | N/A | 62 | 60 | N/A |
| Common Stock Repurchased | -1 | N/A | -16 | -7 | N/A |
| Other Financing Activity | 0 | 126 | 0 | 0 | 529 |
| Financing Cash Flow | $46 | $126 | $46 | $53 | $529 |
| Beginning Cash Position | 34,986 | 25,761 | 25,761 | 25,761 | 16,913 |
| End Cash Position | 56,580 | 34,986 | 52,019 | 12,147 | 25,761 |
| Net Cash Flow | $21,594 | $9,225 | $26,258 | $-13,614 | $8,848 |
| Free Cash Flow | |||||
| Operating Cash Flow | 40,972 | 601 | 13,349 | -23,023 | -31,675 |
| Capital Expenditure | -364 | N/A | -698 | -205 | N/A |
| Free Cash Flow | 40,608 | 601 | 12,651 | -23,228 | -31,675 |